Key Highlights
- Karyopharm (NASDAQ:KPTI) is listed for third-quarter 2026 results on November 20, 2026, but no company date notice was found, and the calendar's loss of USD 1.05 a share is unverified.
- An 8-K dated November 2, 2026 says the company filed Chapter 11 petitions and expects existing Equity to have no value under a prepackaged plan with an Ayrmid merger.
- Second-quarter Revenue was USD 33.4 million against USD 37.9 million, with a net loss of USD 67.0 million, or USD 2.32 a share, versus USD 4.32 a year earlier.
- Cash was USD 65.4 million at June 30, 2026, and the company had said Liquidity would fund operations only into September 2026.
A Listed Date, No Confirmed Notice and a Bankruptcy Backdrop
Karyopharm (NASDAQ:KPTI) appears on the Earnings calendar for November 20, 2026, after the close, for the third quarter. No company announcement of that date was found, and last year's third-quarter results came on November 3, 2025, so the timing is unconfirmed and could change in light of the restructuring. The company, which sells the cancer drug XPOVIO (selinexor), disclosed in an 8-K dated November 2, 2026 that it filed voluntary Chapter 11 petitions in Texas and signed a restructuring support agreement for a Merger between Ayrmid and a reorganized Karyopharm. A calendar Market Capitalisation of USD 394.66 thousand does not reconcile with 22.7 million shares at June 30, so it is omitted.
Second-Quarter Results and Tight Liquidity
For the second quarter of 2026, total revenue was USD 33.4 million against USD 37.9 million a year earlier, while U.S. XPOVIO net product revenue was USD 30.8 million versus USD 29.7 million. The net loss was USD 67.0 million, including USD 32.1 million of mostly non-cash charges tied to embedded Derivatives and warrants. Published coverage, single-source, shows a consensus loss of USD 1.53 a share and revenue of USD 35.82 million, so both lines missed. The company reaffirmed 2026 total revenue guidance of USD 130 million to USD 150 million, XPOVIO revenue of USD 115 million to USD 130 million, and research plus administrative spending of USD 230 million to USD 245 million. The year-ago third quarter had revenue of USD 44.0 million and a loss of USD 3.82 a share, adjusted for a 1-for-15 reverse split.
Equity Wipeout Terms, Bidding Process and the Myelofibrosis Filing
The 8-K states that holders of common stock and convertible preferred stock will not receive any payment under the prepackaged plan, and that the company expects those securities to have no value. Bidding procedures allow other parties to submit competing proposals, and the transaction is expected to close in the first quarter of 2027, subject to plan conditions. For a bankrupt biotech, the metrics that matter are XPOVIO sales, the cash position, the sale process and regulatory milestones. The company planned to submit a supplemental application for selinexor in myelofibrosis in August 2026, and later coverage, single-source, says it was submitted with priority review requested and a filing decision expected in the fourth quarter. Quarterly earnings may matter less to equity holders than the court process. This is not a forecast.
Where Things Stand
Chapter 11 is likely to matter more than the quarterly numbers. Why could it overshadow results at Karyopharm (NASDAQ:KPTI)? Under the prepackaged plan described in the 8-K, existing common holders are not expected to receive any distribution, so earnings affect creditors and bidders more than shareholders. If a report does arrive on November 20, the revenue run rate against guidance, cash and the sale process are the items to read. No verified consensus or confirmed date was found, and trading in a name in bankruptcy can be thin and volatile.






Please wait processing your request...